| Literature DB >> 36157549 |
Zhao-Qing Lu1, Han-Yu Zhang1, Chen-Fen Su1, Yue-Yan Xing1, Guo-Xing Wang1, Chun-Sheng Li2.
Abstract
BACKGROUND: Biliary decompression is well known to greatly decrease the risks of mortality in acute cholangitis (AC). Although early biliary drainage is recommended by the treatment guidelines for AC, the best time for performing this procedure is yet to be established. Furthermore, since the clinical outcomes of patients with severe AC vary dramatically, screening for patients that could benefit the most from early drainage would be more beneficial than the drainage performed based on the severity grade criteria. AIM: To investigate the optimal drainage timing for AC patients with each disease severity grade and organ dysfunction.Entities:
Keywords: Acute cholangitis; Biliary drainage; Endoscopic retrograde cholangiopancreatography; Mortality; Organ dysfunction
Mesh:
Substances:
Year: 2022 PMID: 36157549 PMCID: PMC9367232 DOI: 10.3748/wjg.v28.i29.3934
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.374
Figure 1A flowchart of the study population.
Characteristics data for all patients
|
|
|
|
|
|
|
| Age (yr)-median (IQR) | 74 (63-82) | 66 (59-72.5) | 79 (69-84) | 77 (66-83) | < 0.001 |
| Male, | 783 (60) | 276 (63.7) | 240 (59.3) | 267 (57.2) | 0.123 |
| CCI- median (IQR) | 2 (1-4) | 2 (1-3) | 2 (1-4) | 3 (1-5) | < 0.001 |
| Etiology, | < 0.001 | ||||
| Choledocholithiasis | 906 (69.4) | 315 (72.7) | 252 (62.2) | 339 (72.6) | |
| Malignant obstruction | 242 (18.5) | 73 (16.9) | 97 (24.0) | 72 (15.4) | |
| Benign stenosis | 94 (7.2) | 27 (6.2) | 42 (10.4) | 25 (5.4) | |
| Others | 63 (4.8) | 18 (4.2) | 14 (3.5) | 31 (6.6) | |
| Biliary drainage, | 915 (70.1) | 302 (69.7) | 306 (75.6) | 307 (65.7) | 0.006 |
| LOS (d)-median (IQR) | 11 (8-14) | 11 (8-14) | 11 (7.5-14) | 12 (7-15) | 0.110 |
| Hospitalization cost (CNY)-median (IQR) | 38784.37 (22744.31-53278.63) | 36536.36 (20851.37-47274.77) | 38308.33 (23452.14-52847.29) | 41832.19 (23355.98-58145.52) | < 0.001 |
| IHM, | 41 (3.1) | 1 (0.2) | 7 (1.7) | 33 (7.1) | < 0.001 |
| Survival time of dead (d)-median (IQR) | 8 (3-23.5) | 9 | 23 (13-46) | 6 (3-17) | 0.024 |
| Organ dysfunction | |||||
| Neurological dysfunction | 126 | 0 | 0 | 126 | < 0.001 |
| Respiratory dysfunction | 227 | 0 | 0 | 227 | < 0.001 |
| Renal dysfunction | 64 | 0 | 0 | 64 | < 0.001 |
| Cardiovascular dysfunction | 39 | 0 | 0 | 39 | < 0.001 |
| Hematological dysfunction | 149 | 0 | 0 | 149 | < 0.001 |
| Hepatic dysfunction | 83 | 0 | 0 | 83 | < 0.001 |
| Temperature (℃)-median (IQR) | 37.0 (36.6-38) | 36.8 (36.6-37.8) | 37 (36.6-38.25) | 37.2 (36.6-38.3) | 0.001 |
| Laboratory values | |||||
| WBC (/mm3)-median (IQR) | 10560 (7705-14305) | 9120 (7160-11165) | 12700 (8897-18441) | 11140 (7870-15810) | < 0.001 |
| T-Bil (mg/dL)-median (IQR) | 99.81 (62.43-155.76) | 69.28 (49.625-120.975) | 121.74 (88.97-184.41) | 1041.2 (67.74-156.31) | < 0.001 |
| Albumin (g/L)-median (IQR) | 35.4 (31.2-39.2) | 37.5 (34.2-40.4) | 34.9 (30.8-38.1) | 33.6 (29.2-37.8) | < 0.001 |
| Lactate (mmol/L)-median (IQR) | 2.15 (1.6-3.4) | 1.8 (1.4-2.7) | 2.1 (1.5-2.8) | 2.4 (1.7-4.1) | < 0.001 |
IQR: Interquartile range; CCI: Charlton Comorbidity Index; LOS: Length of stay; CNY: Chinese Yuan; IHM: In-hospital mortality; WBC: White blood cell count; T-Bil: Total bilirubin.
Characteristics data for patients with drainage
|
|
|
|
|
|
|
| Drainage method, | 0.001 | ||||
| ERCP | 830 (90.7) | 289 (95.7) | 269 (87.9) | 272 (88.6) | |
| PTBD | 85 (9.3) | 13 (4.3) | 37 (12.1) | 35 (11.4) | |
| Timing of drainage (hours)- median (IQR), | 24.0 (60.0) | 26.4 (62.4) | 26.4 (62.4) | 21.6 (45.6) | 0.001 |
| Biliary drainage within, | 0.001 | ||||
| 12 h | 212 (23.2) | 54 (17.9) | 69 (22.5) | 89 (29.0) | |
| 12-24 h | 233 (25.5) | 74 (24.5) | 70 (22.9) | 89 (29.0) | |
| 24-48 h | 172 (18.8) | 71 (23.5) | 54 (17.6) | 47 (15.3) | |
| > 48 h | 298 (32.6) | 103 (34.1) | 113 (36.9) | 82 (26.7) | |
| Second intervention, | 478 (52.2) | 159 (52.6) | 154 (50.3) | 165 (53.7) | 0.688 |
| Drainage outside working hours, | 207 (22.6) | 49 (16.2) | 60 (19.6) | 98 (31.9) | < 0.001 |
| Adverse events, | |||||
| Pancreatitis | 75 (8.2) | 23 (7.6) | 23 (7.5) | 29 (9.4) | 0.643 |
| Cholangitis | 8 (0.9) | 2 (0.7) | 2 (0.7) | 4 (1.3) | 0.742 |
| Perforation | 7 (0.8) | 1 (0.3) | 2 (0.7) | 0 (0) | 0.440 |
| Bile leak | 4 (0.4) | 2 (0.7) | 1 (0.3) | 1 (0.3) | 0.701 |
| Myocardial infarction | 5 (0.5) | 0 (0) | 3 (1.0) | 2 (0.7) | 0.339 |
IQR: Interquartile range; ERCP: Endoscopic retrograde cholangiopancreatography; PTBD: Percutaneous transhepatic biliary drainage.
Association of the clinical outcomes in relation to the timing of biliary drainage and severity grading by Tokyo guidelines 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Grade I | IHM | 0/302 | 1/131 | 0.303 | 0/54 | 1/379 | 1.000 | 0/128 | 1/305 | 1.000 | 0/199 | 1/234 | 1.000 | |
| LOS (d) | 11 (9-15) | 7 (4-10) | < 0.001 | 11 (8-13.25) | 10 (8-14) | 0.778 | 11 (8-14) | 10 (7-14) | 0.004 | 11 (8-14) | 10 (6-14) | 0.002 | ||
| Survivors’ LOS (d) ( | 12 (9-15) | 8 (5-11) | < 0.001 | 11 (8-13.25) | 11 (8-14) | 0.794 | 11 (9-14) | 11 (8-14) | 0.065 | 11 (9-14) | 10 (8-14) | 0.101 | ||
| Hospitalization cost (CNY) | 42845.67 (33734.18-52209.23) | 15763.10 (7737.32-23680.31) | < 0.001 | 43328.59 (32863.61-49384.19) | 35317.71 (18848.59-46850.08 | 0.001 | 44154.19 (35638.76-52219.56) | 31292.68 (16269.75-44599.67) | < 0.001 | 42908.34 (33358.44-50564.68) | 25519.43 (12347.06-42424.96) | < 0.001 | ||
| Survivors’ hospitalization cost (CNY) ( | 42957.18 (33973.58-52224.73) | 16596.85 (9096.73-24755.65 | < 0.001 | 43462.72 (36174.00-49384.19) | 36604.86 (21962.98-47554.27) | 0.003 | 44443.3 (35988.02-52237.14) | 33492.6 (46019.17-18880.26) | < 0.001 | 43264.07 (34606.54-51093.62) | 29762.32 (16376.75-44463.21) | < 0.001 | ||
| Grade II | IHM | 2/306 | 5/99 | 0.011 | 0/69 | 7/336 | 0.608 | 0/139 | 7/266 | 0.101 | 1/193 | 6/212 | 0.125 | |
| LOS (d) | 11 (9-15) | 7 (4-12) | < 0.001 | 11 (8-14) | 11 (7-14) | 0.684 | 11 (9-14) | 10 (7-14) | 0.122 | 11 (8-14) | 10 (7-14.8) | 0.190 | ||
| Survivors’ LOS (d) ( | 12 (9-15) | 7.5 (4.75-11.25) | < 0.001 | 11.5 (9-14) | 11 (8-14) | 0.367 | 12 (10-14) | 11 (7-14) | 0.024 | 12 (9-14) | 11 (7-14) | 0.050 | ||
| Hospitalization cost (CNY) | 44033.13 (31071.05-56134.72) | 17626.20 (10037.69-25587.43) | < 0.001 | 45832.44 (36061.53-56949.37) | 36132.93 (21795.89-51453.62) | < 0.001 | 46789.09 (35989.59-57723.15) | 31505.72 (19948.31-47463.61) | < 0.001 | 45489.74 (33858.99-57600.43) | 29275.30 (16928.45-46255.47) | < 0.001 | ||
| Survivors’ hospitalization cost (CNY) ( | 45004.20 (32631.09-56660.62) | 16342.15 (10300.68-25017.80) | < 0.001 | 47938.00 (37937.29-58046.02) | 36629.15 (22828.93-51509.37) | < 0.001 | 48254.61 (37937.29-58929.51) | 31589.96 (20386.80-47062.76) | < 0.001 | 46564.37 (36191.07-57998.63) | 29338.38 (17687.02-45685.12) | < 0.001 | ||
| Grade III | IHM | 11/307 | 22/160 | < 0.001 | 3/89 | 30/378 | 0.168 | 7/178 | 26/289 | 0.041 | 9/225 | 24/242 | 0.018 | |
| LOS (d) | 13 (9-17) | 8 (3-12) | < 0.001 | 13 (11-19) | 11 (6-15) | < 0.001 | 13 (10-17) | 10 (6-14) | < 0.001 | 13 (9-17) | 9.5 (5-14) | < 0.001 | ||
| Survivors’ LOS (d) ( | 13 (11-18) | 9.5 (7-13.25) | <0.001 | 13 (12-19) | 12 (9-16) | 0.001 | 13 (11-17.75) | 12 (9-15) | < 0.001 | 13 (11-17.75) | 11 (8-15) | < 0.001 | ||
| Hospitalization cost | 51583.64 (38985.47-64886.01) | 20183.58 (11317.37-29525.99) | < 0.001 | 56599.94 (43260.73-70300.00) | 38527.58 (21034.79-55279.53) | < 0.001 | 55121.49 (40428.29-67707.01) | 31832.99 (17933.81-50037.89) | < 0.001 | 54295.52 (39252.57-65638.57) | 28165.23 (15708.29-45478.26) | < 0.001 | ||
| Survivors’ hospitalization cost (CNY) ( | 53507.33 (41027.94-65312.29) | 22909.77 (15594.93-31845.39) | < 0.001 | 57976.4 (50131.44-70333.71) | 43241.54 (28347.56-57860.29) | < 0.001 | 55873.84 (46654.40-69946.73) | 38973.06 (24292.41-53090.85) | < 0.001 | 55782.38 (43994.26-66493.67) | 34748.29 (21379.37-50147.24) | < 0.001 | ||
AC: Acute cholangitis; IQR: Interquartile range; IHM: In-hospital mortality; LOS: Length of stay; CNY: Chinese Yuan.
Univariate and multivariate analysis of predictors of mortality, and relationship of mortality with the timing of drainage for each predictor
|
|
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Neurological dysfunction | 8.377 (4.384-16.007) | < 0.001 | 5.32 (2.373-11.931) | < 0.001 | 0/22 | 18/104 | 0.041 | 3/42 | 15/84 | 0.175 | 5/51 | 13/75 | 0.304 |
| Respiratory dysfunction | 2.886 (1.491-5.497) | 0.003 | 2.541 (1.189-5.43) | 0.016 | 1/44 | 14/183 | 0.314 | 4/91 | 11/136 | 0.414 | 6/117 | 9/110 | 0.428 |
| Renal dysfunction | 11.043 (5.402-22.573) | < 0.001 | 6.356 (2.623-15.397) | < 0.001 | 1/15 | 12/49 | 0.269 | 1/28 | 12/36 | 0.004 | 1/31 | 12/33 | 0.001 |
| Cardiovascular dysfunction | 11.569 (5.078-26.357) | < 0.001 | 4.021 (1.361-11.88) | 0.012 | 0/7 | 9/32 | 0.169 | 2/16 | 7/23 | 0.262 | 2/18 | 7/21 | 0.139 |
| Hematological dysfunction | 2.611 (1.253-5.441) | 0.02 | N/A | 2/37 | 8/104 | 1 | 3/61 | 7/88 | 0.527 | 3/74 | 7/75 | 0.327 | |
| Hepatic dysfunction | 5.263 (2.484-11.152) | < 0.001 | N/A | 0/15 | 10/68 | 0.196 | 1/30 | 9/53 | 0.086 | 1/39 | 9/44 | 0.016 | |
| Age (≥ 75 yr) | 1.432 (0.765-2.680) | 0.261 | N/A | 2/88 | 21/531 | 0.759 | 4/196 | 19/423 | 0.172 | 7/267 | 16/352 | 0.284 | |
| Temperature (≥ 39 ℃) | 0.390 (0.093-1.631) | 0.197 | N/A | 0/43 | 2/106 | 1 | 1/75 | 1/74 | 1 | 1/85 | 1/64 | 1 | |
| WBC (> 12000/mm3, < 4000/mm3) | 1.962 (1.043-3.688) | 0.036 | N/A | 1/107 | 23/445 | 0.063 | 4/207 | 20/342 | 0.031 | 6/278 | 18/275 | 0.012 | |
| T-Bil (≥ 5 mg/dL) | 1.711 (0.865-3.385) | 0.123 | N/A | 3/143 | 26/626 | 0.333 | 5/292 | 24/477 | 0.019 | 8/407 | 21/362 | 0.007 | |
| Albumin (< STD*0.7) | 10.715 (5.147-22.303) | < 0.001 | 5.655 (2.398-13.335) | < 0.001 | 0/8 | 12/51 | 0.188 | 0/15 | 12/44 | 0.026 | 1/24 | 11/35 | 0.018 |
| Lactate (≥ 2 mmol/L) | 1.450 (0.766-2.747) | 0.254 | N/A | 0/105 | 16/298 | 0.016 | 2/186 | 14/217 | 0.008 | 4/227 | 12/176 | 0.018 | |
| Malignant obstruction | 5.495 (2.924-10.325) | < 0.001 | 7.522 (3.504-16.149) | < 0.001 | 1/26 | 21/216 | 0.483 | 2/59 | 20/183 | 0.116 | 3/101 | 19/141 | 0.006 |
| CCI (> 3) | 4.080 (2.153-7.7340) | < 0.001 | N/A | 2/57 | 23/318 | 0.397 | 4/127 | 21/248 | 0.052 | 6/177 | 19/198 | 0.021 | |
WBC: White blood cell count; T-Bil: Total bilirubin; STD: Lower limit of normal value; CCI: Charlton Comorbidity Index; OR: Odds ratio; CI: Confidence interval; N/A: Not applicable.